Novel NO-releasing scopoletin derivatives induce cell death via mitochondrial apoptosis pathway and cell cycle arrest

Zhixian Shi,Na Li,Cheng Chen,Yujin Wang,Zhichao Lei,Li Chen,Jianbo Sun
DOI: https://doi.org/10.1016/j.ejmech.2020.112386
IF: 7.088
2020-08-01
European Journal of Medicinal Chemistry
Abstract:<p>A series of phenylsulfonyfuroxan-based NO-releasing scopoletin derivatives were designed and synthesized in the study. All target compounds showed significantly improved antiproliferative activity against four cancer cell lines (MDA-MB-231, MCF-7, HepG2 and A459) and lower cytotoxicity toward normal liver LO2 cells. Derivative <strong>47</strong> concentration-dependently inhibited the colony formation of MDA-MB-231 cells. NO-releasing assessment indicated that the intracellular NO level was almost positively correlated with the antiproliferative ability. Compound <strong>47</strong>, which released the highest amounts of NO, showed the best potency (IC<sub>50</sub> = 1.23 μM) against MDA-MB-231 cells. Mechanism research revealed for the first time that <strong>47</strong> blocked the proliferation of MDA-MB-231 cells by activating mitochondrial apoptosis pathway and arresting cell cycle at G2/M phase. Taken together, as a novel scopoletin derivative, <strong>47</strong> exhibited excellent inhibitory effects against malignant cancer cells and lower toxicity on normal cells. Thus, an in-depth evaluation of <strong>47</strong> to explore its complete therapeutic potential for cancer treatment is warranted.</p>
chemistry, medicinal
What problem does this paper attempt to address?